A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
A 3-Part, Open-Label, Randomized, 2-Period Crossover Study to Demonstrate the Definitive Bioequivalence After Administration of the FMI Sitagliptin/Metformin 50/500 mg, 50/850 mg and 50/1000 mg FDC Tablet and Co-administration of Corresponding Doses of Sitagliptin and Metformin as Individual Tablets
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Drug: sitagliptin phosphate (+) metformin hydrochloride
- Drug: Comparator: metformin 500mg
- Drug: Comparator: sitagliptin
- Drug: Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet
- Drug: Comparator: metformin 1000 mg
- Drug: Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
- Drug: Comparator: metformin 850 mg
- Drug: Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female subjects of reproductive potential test negative for pregnancy and agree to use appropriate contraception
- Subject is in good health and is a non-smoker
Exclusion Criteria:
- Subject has a history of neoplastic disease (cancer), stroke, chronic seizures, or major neurological disorder
- Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
- Subject is a nursing mother
- Subject consumes excessive amounts of alcohol or caffeine
- Subject has donated blood, had surgery or participated in another clinical study within the past 4 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Treatment A
50 mg sitagliptin and 500 mg metformin as individual tablets
|
place holder - do not post
A single dose of metformin 500 mg tablet
Other Names:
A single dose of 50 mg sitagliptin tablet
Other Names:
|
|
Experimental: Treatment B
sitagliptin/metformin 50 mg/500 mg tablet
|
A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
|
|
Active Comparator: Treatment C
50 mg sitagliptin and 1000 mg metformin as individual tablets
|
A single dose of 50 mg sitagliptin tablet
Other Names:
A single dose of metformin 1000 mg tablet
Other Names:
|
|
Experimental: Treatment D
sitagliptin/metformin 50 mg/1000 mg tablet
|
A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
|
|
Active Comparator: Treatment E
50 mg sitagliptin and 850 mg metformin as individual tablets
|
A single dose of 50 mg sitagliptin tablet
Other Names:
A single dose of metformin 850 mg tablet
Other Names:
|
|
Experimental: Treatment F
sitagliptin/metformin 50 mg/850 mg tablet
|
A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The area under the plasma concentration-time curve (AUC) after administration of sitagliptin/metformin (50/500; 50/850; 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.
Time Frame: Up to 72 hours postdose
|
Up to 72 hours postdose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Peak plasma concentration (Cmax) for metformin after administration of sitagliptin/metformin (50/500; 50/850, 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.
Time Frame: Up to 72 hours postdose
|
Up to 72 hours postdose
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0431A-095
- MK0431A-095
- 2009_636
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.